ASH 2019 updates on Minimal Residual Disease (MRD)

Minimal Residual Disease (MRD) is one of the big topics in myeloma. Different techniques to measure MRD and new data about its role in predicting the risk of relapse are some of the topics discussed during the American Society of Hematology (ASH) Annual Meeting. In this video Dr Francesca Gay, University of Torino, Italy, explains for Myeloma Patients Europe (MPE) what was presented at ASH 2019 regarding MRD and the unanswered questions about its role…

ASH 2019 CAR-T cell therapy in myeloma

  CAR-T cell therapy is one of the most promising treatments in a number of types of cancer. In myeloma, very promising results were presented during the American Society of Hematology (ASH) Annual Meeting. Dr Mohamad Mohty, Head of Haematology and and celular therapy department, Saint-Antoine Hospital and University Pierre & Marie Curie, Paris, France, summarises for Myeloma Patients Europe (MPE) the most important CAR-T cells updates in myeloma at ASH.

Dreamm-3, the clinical trial on the new myeloma drug belantamab mafodotin, presented at ASH 2019

  ASH 2019, Orlando – Belantamab mafodotin is a new myeloma drug that has shown very promising results. The clinical trial Dreamm-3 was presented yesterday at the American Society of Hematology (ASH) Annaul Congress and it is expected to be the European approval trial for this drug. Dr Katja Weisel, University Medical Center Hamburg-Eppendorf in Germany, explains for Myeloma Patients Europe (MPE) what we need to know about this first-in-class drug.

Second-generation CAR T-cell products may overcome resistance, reduce toxicity and simplify treatment

  ASH 2019, Orlando – A number of early-phase studies were presented yesterday during the 61st American Society of Hematology (ASH) Annual Meeting spotlight the rapid advances being made in cellular immunotherapy for blood cancers. Researchers will present the results of early-phase studies of emerging “second-generation” cellular immunotherapy products that strive to overcome the limitations of existing products.